{"nctId":"NCT02047227","briefTitle":"Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)","startDateStruct":{"date":"2014-01-31","type":"ACTUAL"},"conditions":["Infertility"],"count":939,"armGroups":[{"label":"Pergoveris®","type":"EXPERIMENTAL","interventionNames":["Drug: Pergoveris®","Drug: Recombinant human chorionic gonadotrophin (r-hCG)"]},{"label":"GONAL-f®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: GONAL-f®","Drug: Recombinant human chorionic gonadotrophin (r-hCG)"]}],"interventions":[{"name":"Pergoveris®","otherNames":["r-hFSH/r-hLH","Follitropin alfa/Lutropin alfa"]},{"name":"GONAL-f®","otherNames":["r-hFSH","Follitropin alfa"]},{"name":"Recombinant human chorionic gonadotrophin (r-hCG)","otherNames":["Ovidrel®","Ovitrelle®","choriogonadotropin alfa"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Poor ovarian responders according to specific criteria that are aligned with poor ovarian response (POR) criteria defined by the 2011 Consensus Meeting of the European Society of Human Reproduction and Embryology (ESHRE) as mentioned in the protocol\n* Female subjects, less than (\\<) 41 years of age (according to date of birth at time of informed consent) who are eligible for ovarian stimulation and ART treatment, including intracytoplasmic sperm injection (ICSI)\n* Absence of anatomical abnormalities of the reproductive tract that would interfere with implantation or pregnancy\n* Absence of any medical condition in which pregnancy is contraindicated\n* Body mass index 18 to 30 kilogram per square meter (kg/m\\^2), inclusive\n* Motile, ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed). Intracytoplasmic sperm injection will be allowed during this trial\n* Minimum of 1 month without treatment with either clomiphene citrate or gonadotrophins prior to screening\n* Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment\n\nExclusion Criteria:\n\n* Two episodes of POR after maximal stimulation\n* History or presence of tumors of the hypothalamus or pituitary gland\n* History or presence of ovarian enlargement or cyst of unknown etiology, or presence of an ovarian cyst greater than 25 mm on the day of randomization\n* Presence of endometriosis Grade III - IV, confirmed or suspected\n* Presence of uni- or bilateral hydrosalpinx\n* Abnormal gynecological bleeding of undetermined origin\n* Contraindication to being pregnant and/or carrying a pregnancy to term\n* History or presence of ovarian, uterine or mammary cancer\n* Use of testicular or epididymal sperm\n* Other protocol defined exclusion criteria could apply","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"41 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Oocytes Retrieved","description":"Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"2.71"},{"groupId":"OG001","value":"3.6","spread":"2.82"}]}]}]},{"type":"SECONDARY","title":"Ongoing Pregnancy Rate","description":"Ongoing pregnancy rate was defined as the percentage of subjects with a ultrasound confirmation of at least one viable fetus (positive fetal heart beat).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"12.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Live Birth Rate","description":"Live birth rate was defined as the percentage of subjects with at least one live-born neonate.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Embryo Implantation Rate","description":"Embryo implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":null},{"groupId":"OG001","value":"15.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Pregnancy Rate","description":"Clinical pregnancy rate defined as the percentage of subjects with a ultrasound confirmation of a gestational sac, with or without fetal heart activity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"16.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Biochemical Pregnancy Rate","description":"Biochemical pregnancy rate was defined as the percentage of subjects with a positive beta-hCG result from the serum pregnancy test.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"23.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":462},"commonTop":["Headache","Hot flush","Nausea","Abdominal pain","Abortion spontaneous"]}}}